Search

Your search keyword '"Agnandji, Selidji T."' showing total 270 results
Start Over Author "Agnandji, Selidji T."
270 results on '"Agnandji, Selidji T."'

1. Performance evaluation of a combination Plasmodium dual-antigen CRP rapid diagnostic test in Lambaréné, Gabon

Author

Alabi, Ayodele, Musangomunei, Fungai P., Lotola-Mougeni, Fabrice, Bie-Ondo, Juste C., Murphy, Kristin, Essone, Paulin N., Kabwende, Anita L., Mahmoudou, Saidou, Macé, Aurélien, Harris, Victoria, Ramharter, Michael, Grobusch, Martin P., Yazdanbakhsh, Maria, Fernandez-Carballo, B. Leticia, Escadafal, Camille, Kremsner, Peter G., Dittrich, Sabine, and Agnandji, Selidji T.

Published
2024
Full Text
View/download PDF

2. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon

Author

Alabi, Ayodele, Kokou, Kossiwa, Mahmoudou, Saidou, Kavishna, Ranmali, Nakka, Sravya S., Rothenberger, Sylvia, Musangomunei, Fungai P., Olubiyi, Bisola F., Bie-Ondo, Juste C., Kabwende, Anita L., Velavan, Thirumalaisamy P., Medaglini, Donata, Nakaya, Helder I., Engler, Olivier, Harandi, Ali M., Siegrist, Claire-Anne, Kremsner, Peter G., and Agnandji, Selidji T.

Published
2024
Full Text
View/download PDF

3. Prostration and the prognosis of death in African children with severe malaria

Author

Agnandji, Selidji T., Recker, Mario, Mordmüller, Benjamin, Glöckner, Stephan, Adegnika, Akim A., Lell, Bertrand, Otieno, Lucas, Otieno, Walter, Owusu-Agyei, Seth, Asante, Kwaku P., Agbenyega, Tsiri, Ansong, Daniel, Macete, Eusebio, Aide, Pedro, Sorgho, Hermann, Tinto, Halidou, Mturi, Neema, Lusingu, John P.A., Gesase, Samwel, Hoffman, Irving, Masoud, Nahya Salim, Newton, Charles R., Bojang, Kalifa, Krause, Gérard, and Kremsner, Peter Gottfried

Published
2023
Full Text
View/download PDF

4. Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambaréné, Gabon

Author

Essone, Paulin N., Adegbite, Bayode R., Mbadinga, Marien J. M., Mbouna, Armel V., Lotola-Mougeni, Fabrice, Alabi, Ayodele, Edoa, Jean R., Lell, Bertrand, Alabi, Abraham S., Adegnika, Ayola A., Ramharter, Michael, Siawaya, Joel F. D., Grobusch, Martin P., Kremsner, Peter G., and Agnandji, Selidji T.

Published
2022
Full Text
View/download PDF

5. Single and Combined Serum Proteins Expressed in TB Infection are Candidates for Point-of-care Diagnostic Testing of Active TB Patients in Lambaréné, Gabon.

Author

Essone, Paulin N, Lotola-Mougeni, Fabrice, Adegbite, Bayode R, Kokou, Kossiwa, N'Nang, E Otogo, Mabicka, Eddy, Alabi, Ayodele, Siawaya, Joel F Djoba, Kremsner, Peter G, Grobusch, Martin P, and Agnandji, Selidji T

Subjects
BLOOD proteins, COMMUNITY-acquired pneumonia, RAPID tooling, POINT-of-care testing, TUBERCULOSIS
Abstract

Background and Objectives Point-of-care testing using nonsputum samples like serum or plasma proteins can improve tuberculosis (TB) patients access to a definitive diagnosis, especially in resource-constrained and remote areas. Recently, approximately 400 proteins were identified as playing a role in the pathogenesis of TB, offering a translational clinical research repository for TB. In a previous manuscript, we proved the potential use of these proteins for point-of-care testing for active TB diagnosis. The present work aims to confirm the performance of single and combination proteins to select the best candidate biomarkers for further development as a diagnostic testing tool for active TB. Methods Seventy-four participants were assessed on the diagnostic performance of 17 single proteins and combinations of 2 to 4 proteins to diagnose active TB. The selection criteria included differential expression of the proteins between active TB and community-acquired pneumonia (CAP) and a performance rate ≥70% for active TB. Results SULT4A1, WASPF3, SPTLC1, FAM107B, SORCS2, and CYTOb561 were differentially expressed in TB compared to CAP patients. Two single proteins, SULT4A1 and WASPF3, performed ≥70% to discriminate active TB from CAP patients. The diagnostic performance of 3 protein-based combinations of active TB was 81% after leave-one-out cross-validation. Conclusion Single proteins and 3 protein-based combinations are candidate biomarkers for diagnosing active TB disease. A large and prospective study will confirm their performance as complementary diagnostic tools to rapid diagnostic methods for detecting active TB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Identification of potential novel hosts and the risk of infection with lymphocytic choriomeningitis virus in humans in Gabon, Central Africa

Author

Ushijima, Yuri, Abe, Haruka, Ozeki, Takehiro, Ondo, Georgelin N., Mbadinga, Marien J.V.M., Bikangui, Rodrigue, Nze-Nkogue, Chimène, Akomo-Okoue, Etienne F., Ella, Ghislain W.E., Koumba, Lilian B.M., Nso, Branly C.B.B., Mintsa-Nguema, Rodrigue, Makouloutou-Nzassi, Patrice, Makanga, Boris K., Nguelet, Fred L.M., Zadeh, Vahid R., Urata, Shuzo, Mbouna, Armel V.N., Massinga-Loembe, Marguerite, Agnandji, Selidji T., Lell, Bertrand, and Yasuda, Jiro

Published
2021
Full Text
View/download PDF

7. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial

Author

Mouwenda, Yoanne D, Betouke Ongwe, Eunice, Nkoma Mouima, Anne-Marie, Nouatin, Odilon P, Edoa, Jean R, Manouana, Prince G, Pinto de Jesus, Susana, Kühne, Vera, Mordmueller, Benjamin, Lell, Bertrand, Agnandji, Selidji T, Koehler, Carsten, Adegnika, Ayola A, de Vries, Sophia G, Zinsou, Frejus J, Honkepehedji, Yabo J, Dejon Agobé, Jean-Claude, Vodonou, Kafui G, Bikangui, Rodrigue, Bouyoukou Hounkpatin, Aurore, Bache, Emmanuel B, Massinga Loembe, Marguerite, van Leeuwen, Remko, Molemans, Marjan, Kremsner, Peter G, Yazdanbakhsh, Maria, Hotez, Peter J, Bottazzi, Maria Elena, Li, Guangzhao, Bethony, Jeffrey M, Diemert, David J, and Grobusch, Martin P

Published
2021
Full Text
View/download PDF

8. Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon

Author

Ramharter, Michael, Agnandji, Selidji T., Adegnika, Ayôla A., Lell, Bertrand, Mombo-Ngoma, Ghyslain, Grobusch, Martin P., McCall, Matthew, Muranaka, Riko, Kreidenweiss, Andrea, Velavan, Thirumalaisamy P., Esen, Meral, Schaumburg, Frieder, Alabi, Abraham, Druml, Christiane, Mordmüller, Benjamin, Köhler, Carsten, and Kremsner, Peter G.

Published
2021
Full Text
View/download PDF

14. Making clinical trials a public norm for health decisions in sub-Saharan Africa.

Author

Agnandji, Selidji T., Loembe, Marguerite Massinga, Mbouna, Armel V., Mbadinga, Fallowne, Essone, Paulin N., Mombo-Ngoma, Ghyslain, Leke, Rose, Mburu, Yvonne K., Muyembe-Tamfum, Jean-Jacques, Okwo-Bele, Jean-Marie, Sow, Samba, Wiysonge, Charles Shey, Zumla, Alimuddin, Adegnika, Ayola A., Ramharter, Michael, Kremsner, Peter G., Matsiegui, Pierre-Blaise, Boum, Yap, and Ntoumi, Francine

Published
2024
Full Text
View/download PDF

15. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial

Author

Zoleko-Manego, Rella, primary, Kreuzmair, Ruth, additional, Veletzky, Luzia, additional, Ndzebe-Ndoumba, Wilfrid, additional, Ekoka Mbassi, Dorothea, additional, Okwu, Dearie G., additional, Dimessa-Mbadinga-Weyat, Lia B., additional, Houtsa-Temgoua, Roselyne D., additional, Mischlinger, Johannes, additional, McCall, Matthew B. B., additional, Kresmner, Peter G., additional, Agnandji, Selidji T., additional, Lell, Betrand, additional, Adegnika, Ayôla A., additional, Mombo-Ngoma, Ghyslain, additional, and Ramharter, Michael, additional

Published
2023
Full Text
View/download PDF

16. Genetic Diversity of Hepatitis B and C Viruses Revealed by Continuous Surveillance from 2015 to 2021 in Gabon, Central Africa

Author

Abe, Haruka, primary, Ushijima, Yuri, additional, Bikangui, Rodrigue, additional, Ondo, Georgelin Nguema, additional, Pemba, Christelle M., additional, Zadeh, Vahid R., additional, Mpingabo, Patrick I., additional, Ueda, Hayato, additional, Agnandji, Selidji T., additional, Lell, Bertrand, additional, and Yasuda, Jiro, additional

Published
2023
Full Text
View/download PDF

17. Unique Evolution Patterns of Hepatitis B and C Viruses Revealed by Continuous Genetic Surveillance from 2015 to 2021 in Gabon, Central Africa

Author

Abe, Haruka, primary, Ushijima, Yuri, additional, Bikangui, Rodrigue, additional, Ondo, Georgelin Nguema, additional, Pemba, Christelle M., additional, Zadeh, Vahid R., additional, Mpingabo, Patrick I., additional, Ueda, Hayato, additional, Agnandji, Selidji T., additional, Lell, Bertrand, additional, and Yasuda, Jiro, additional

Published
2023
Full Text
View/download PDF

18. Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees

Author

Moncunill, Gemma, Mpina, Maxmillian, Nhabomba, Augusto J., Aguilar, Ruth, Ayestaran, Aintzane, Sanz, Héctor, Campo, Joseph J., Jairoce, Chenjerai, Barrios, Diana, Dong, Yan, Díez-Padrisa, Núria, Fernandes, José F., Abdulla, Salim, Sacarlal, Jahit, Williams, Nana A., Harezlak, Jaroslaw, Mordmüller, Benjamin, Agnandji, Selidji T., Aponte, John J., Daubenberger, Claudia, Valim, Clarissa, and Dobaño, Carlota

Published
2017

19. Genetic Diversity of Hepatitis B and C Viruses Revealed by Continuous Surveillance from 2015 to 2021 in Gabon, Central Africa

Author

Abe, Haruka, Ushijima, Yuri, Bikangui, Rodrigue, Ondo, Georgelin Nguema, Pemba, Christelle M., Zadeh, Vahid R., Mpingabo, Patrick I., Ueda, Hayato, Agnandji, Selidji T., Lell, Bertrand, Yasuda, Jiro, Abe, Haruka, Ushijima, Yuri, Bikangui, Rodrigue, Ondo, Georgelin Nguema, Pemba, Christelle M., Zadeh, Vahid R., Mpingabo, Patrick I., Ueda, Hayato, Agnandji, Selidji T., Lell, Bertrand, and Yasuda, Jiro

Abstract

Viral hepatitis remains one of the largest public health concerns worldwide. Especially in Central Africa, information on hepatitis virus infections has been limited, although the prevalence in this region has been reported to be higher than the global average. To reveal the current status of hepatitis B and C virus (HBV and HCV) infections and the genetic diversity of the viruses, we conducted longitudinal surveillance in Gabon. We detected 22 HBV and 9 HCV infections in 2047 patients with febrile illness. Genetic analyses of HBV identified subgenotype A1 for the first time in Gabon and an insertion generating a frameshift to create an X-preC/C fusion protein. We also revealed that most of the detected HCVs belonged to the “Gabon-specific” HCV subtype 4e (HCV-4e), and the entire nucleotide sequence of the HCV-4e polyprotein was determined to establish the first reference sequence. The HCV-4e strains possessed resistance-associated substitutions similar to those of other HCV-4 strains, indicating that the use of direct-acting antiviral therapy may be complex. These results provide a better understanding of the current situation of hepatitis B and C virus infections in Central Africa and will help public health organizations develop effective countermeasures to eliminate chronic viral hepatitis in this region., Microorganisms, 11(8), art. no. 2046; 2023

Published
2023

20. Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

Author

Adegbite, Bayode R., Edoa, Jean R., Honkpehedji, Yabo J., Zinsou, Frejus J., Dejon-Agobe, Jean C., Mbong-Ngwese, Mirabeau, Lotola-Mougueni, Fabrice, Koehne, Erik, Lalremruata, Albert, Kreidenweiss, Andrea, Nguyen, The T., Kun, Jutta, Agnandji, Selidji T., Lell, Bertrand, Safiou, Abdou R., Obone Atome, Fridia A., Mombo-Ngoma, Ghyslain, Ramharter, Michael, Velavan, Thirumalaisamy P., Mordmüller, Benjamin, Kremsner, Peter G., and Adegnika, Ayola A.

Published
2019
Full Text
View/download PDF

21. Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study

Author

Tona Lutete, Gaston, Mombo-Ngoma, Ghyslain, Assi, Serge-Brice, Bigoga, Jude D., Koukouikila-Koussounda, Felix, Ntamabyaliro, Nsengi Y., Ntoumi, Francine, Agnandji, Selidji T., Groger, Mirjam, Shin, Jangsik, Borghini-Fuhrer, Isabelle, Arbe-Barnes, Sarah, Allen, Stephen J., Kremsner, Peter G., Miller, Robert, Duparc, Stephan, and Ramharter, Michael

Subjects
Antimalarials -- Dosage and administration -- Patient outcomes, Drug therapy, Combination -- Methods -- Patient outcomes, Malaria -- Drug therapy -- Patient outcomes, Biological sciences
Abstract

Background In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated malaria, pyronaridine-artesunate demonstrated high efficacy and a safety profile consistent with that of comparators, except that asymptomatic, mainly mild-to-moderate transient increases in liver aminotransferases were reported for some patients. Hepatic safety, tolerability, and effectiveness have not been previously assessed under real-world conditions in Africa. Methods and findings This single-arm, open-label, cohort event monitoring study was conducted at 6 health centers in Cameroon, Democratic Republic of Congo, Gabon, Ivory Coast, and Republic of Congo between June 2017 and April 2019. The trial protocol as closely as possible resembled real-world clinical practice for the treatment of malaria at the centers. Eligible patients were adults or children of either sex, weighing at least 5 kg, with acute uncomplicated malaria who did not have contraindications for pyronaridine-artesunate treatment as per the summary of product characteristics. Patients received fixed-dose pyronaridine-artesunate once daily for 3 days, dosed by body weight, without regard to food intake. A tablet formulation was used in adults and adolescents and a pediatric granule formulation in children and infants under 20 kg body weight. The primary outcome was the hepatic event incidence, defined as the appearance of the clinical signs and symptoms of hepatotoxicity confirmed by a >2x rise in alanine aminotransferase/aspartate aminotransferase (ALT/AST) versus baseline in patients with baseline ALT/AST >2x the upper limit of normal (ULN). As a secondary outcome, this was assessed in patients with ALT/AST >2x ULN prior to treatment versus a matched cohort of patients with normal baseline ALT/AST. The safety population comprised 7,154 patients, of mean age 13.9 years (standard deviation (SD) 14.6), around half of whom were male (3,569 [49.9%]). Patients experienced 8,560 malaria episodes; 158 occurred in patients with baseline ALT/AST elevations >2xULN. No protocol-defined hepatic events occurred following pyronaridine-artesunate treatment of malaria patients with or without baseline hepatic dysfunction. Thus, no cohort comparison could be undertaken. Also, as postbaseline clinical chemistry was only performed where clinically indicated, postbaseline ALT/AST levels were not systematically assessed for all patients. Adverse events of any cause occurred in 20.8% (1,490/7,154) of patients, most frequently pyrexia (5.1% [366/7,154]) and vomiting (4.2% [303/7,154]). Adjusting for Plasmodium falciparum reinfection, clinical effectiveness at day 28 was 98.6% ([7,369/7,746] 95% confidence interval (CI) 98.3 to 98.9) in the per-protocol population. There was no indication that comorbidities or malnutrition adversely affected outcomes. The key study limitation was that postbaseline clinical biochemistry was only evaluated when clinically indicated. Conclusions Pyronaridine-artesunate had good tolerability and effectiveness in a representative African population under conditions similar to everyday clinical practice. These findings support pyronaridine-artesunate as an operationally useful addition to the management of acute uncomplicated malaria. Trial registration ClinicalTrials.gov NCT03201770., Author(s): Gaston Tona Lutete 1, Ghyslain Mombo-Ngoma 2,3,4, Serge-Brice Assi 5, Jude D. Bigoga 6, Felix Koukouikila-Koussounda 7, Nsengi Y. Ntamabyaliro 1, Francine Ntoumi 3,7, Selidji T. Agnandji 2,3, Mirjam [...]

Published
2021
Full Text
View/download PDF

23. Performance of Field’s Stain Compared with Conventional Giemsa Stain for the Rapid Detection of Blood Microfilariae in Gabon

Author

Ekoka Mbassi, Franck-A., primary, Mombo-Ngoma, Ghyslain, additional, Ndoumba, Wilfrid Ndzebe, additional, Yovo, Emmanuel K., additional, Eberhardt, Kirsten A., additional, Ekoka Mbassi, Dorothea, additional, Adegnika, Ayôla A., additional, Agnandji, Selidji T., additional, Bouyou-Akotet, Marielle K., additional, Ramharter, Michael, additional, and Zoleko-Manego, Rella, additional

Published
2022
Full Text
View/download PDF

25. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study

Author

Moncunill, Gemma, primary, Carnes, Jason, additional, Chad Young, William, additional, Carpp, Lindsay, additional, De Rosa, Stephen, additional, Campo, Joseph J, additional, Nhabomba, Augusto, additional, Mpina, Maxmillian, additional, Jairoce, Chenjerai, additional, Finak, Greg, additional, Haas, Paige, additional, Muriel, Carl, additional, Van, Phu, additional, Sanz, Héctor, additional, Dutta, Sheetij, additional, Mordmüller, Benjamin, additional, Agnandji, Selidji T, additional, Díez-Padrisa, Núria, additional, Williams, Nana Aba, additional, Aponte, John J, additional, Valim, Clarissa, additional, Neafsey, Daniel E, additional, Daubenberger, Claudia, additional, McElrath, M Juliana, additional, Dobaño, Carlota, additional, Stuart, Ken, additional, and Gottardo, Raphael, additional

Published
2022
Full Text
View/download PDF

26. Evaluation of the Safety and Immunogenicity of the RTS,S/AS01 E Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

Author

Agnandji, Selidji T., Asante, Kwaku Poku, Lyimo, John, Vekemans, Johan, Soulanoudjingar, Solange S., Owusu, Ruth, Shomari, Mwanajaa, Leach, Amanda, Fernandes, Jose, Dosoo, David, Chikawe, Maria, Issifou, Saadou, Osei-Kwakye, Kingsley, Lievens, Marc, Paricek, Maria, Apanga, Stephen, Mwangoka, Grace, Okissi, Blaise, Kwara, Evans, Minja, Rose, Lange, Jorn, Boahen, Owusu, Kayan, Kingsley, Adjei, George, Chandramohan, Daniel, Jongert, Erik, Demoitié, Marie-Ange, Dubois, Marie-Claude, Carter, Terrel, Vansadia, Preeti, Villafana, Tonya, Sillman, Marla, Savarese, Barbara, Lapierre, Didier, Ballou, William Ripley, Greenwood, Brian, Tanner, Marcel, Cohen, Joe, Kremsner, Peter G., Lell, Bertrand, Owusu-Agyei, Seth, and Abdulla, Salim

Published
2010

29. Intermittent Preventive Treatment against Malaria in Infants in Gabon: A Randomized, Double-Blind, Placebo-Controlled Trial

Author

Grobusch, Martin P., Lell, Bertrand, Schwarz, Norbert G., Gabor, Julian, Dörnemann, Jenny, Pötschke, Marc, Oyakhirome, Sunny, Kiessling, Georg C., Necek, Magdalena, Längin, Matthias U., Klouwenberg, Peter Klein, Klöpfer, Anna, Naumann, Benjamin, Altun, Handan, Agnandji, Selidji T., Goesch, Julia, Decker, Marieluise, Ospina Salazar, Carmen L., Supan, Christian, Kombila, Davy U., Borchert, Lea, Köster, Kai B., Pongratz, Peter, Adegnika, Akim A., von Glasenapp, Isabelle, Issifou, Saadou, and Kremsner, Peter G.

Published
2007
Full Text
View/download PDF

30. Author response: Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study

Author

Moncunill, Gemma, primary, Carnes, Jason, additional, Chad Young, William, additional, Carpp, Lindsay, additional, De Rosa, Stephen, additional, Campo, Joseph J, additional, Nhabomba, Augusto, additional, Mpina, Maxmillian, additional, Jairoce, Chenjerai, additional, Finak, Greg, additional, Haas, Paige, additional, Muriel, Carl, additional, Van, Phu, additional, Sanz, Héctor, additional, Dutta, Sheetij, additional, Mordmüller, Benjamin, additional, Agnandji, Selidji T, additional, Díez-Padrisa, Núria, additional, Williams, Nana Aba, additional, Aponte, John J, additional, Valim, Clarissa, additional, Neafsey, Daniel E, additional, Daubenberger, Claudia, additional, McElrath, M Juliana, additional, Dobaño, Carlota, additional, Stuart, Ken, additional, and Gottardo, Raphael, additional

Published
2021
Full Text
View/download PDF

31. Clinical and Parasitological Characteristics of Puerperal Malaria

Author

Ramharter, Michael, Grobusch, Martin P., KieBling, Georg, Adegnika, Ayola A., Moller, Ulrike, Agnandji, Selidji T. M., Kramer, Martin, Schwarz, Norbert, Kun, Jürgen F. J., Oyakhirome, Sunny, Issifou, Saadou, Borrmann, Steffen, Lell, Bertrand, Mordmüller, Benjamin, and Kremsner, Peter G.

Published
2005

32. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Author

Agnandji, Selidji T., Huttner, Angela, Zinser, Madeleine E., Njuguna, Patricia, Dahlke, Christine, Fernandes, José F., Yerly, Sabine, Dayer, Julie-Anne, Kraehling, Verena, Kasonta, Rahel, Adegnika, Akim A., Altfeld, Marcus, Auderset, Floriane, Bache, Emmanuel B., Biedenkopf, Nadine, Borregaard, Saskia, Brosnahan, Jessica S., Burrow, Rebekah, Combescure, Christophe, Desmeules, Jules, Eickmann, Markus, Fehling, Sarah K., Finckh, Axel, Goncalves, Ana Rita, Grobusch, Martin P., Hooper, Jay, Jambrecina, Alen, Kabwende, Anita L., Kaya, Gürkan, Kimani, Domtila, Lell, Bertrand, Lemaître, Barbara, Lohse, Ansgar W., Massinga-Loembe, Marguerite, Matthey, Alain, Mordmüller, Benjamin, Nolting, Anne, Ogwang, Caroline, Ramharter, Michael, Schmidt-Chanasit, Jonas, Schmiedel, Stefan, Silvera, Peter, Stahl, Felix R., Staines, Henry M., Strecker, Thomas, Stubbe, Hans C., Tsofa, Benjamin, Zaki, Sherif, Fast, Patricia, Moorthy, Vasee, Kaiser, Laurent, Krishna, Sanjeev, Becker, Stephan, Kieny, Marie-Paule, Bejon, Philip, Kremsner, Peter G., Addo, Marylyn M., and Siegrist, Claire-Anne

Published
2016
Full Text
View/download PDF

33. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

Author

Neafsey, Daniel E., Juraska, Michal, Bedford, Trevor, Benkeser, David, Valim, Clarissa, Griggs, Allison, Lievens, Marc, Abdulla, Salim, Adjei, Samuel, Agbenyega, Tsiri, Agnandji, Selidji T., Aide, Pedro, Anderson, Scott, Ansong, Daniel, Aponte, John J., Asante, Kwaku Poku, Bejon, Philip, Birkett, Ashley J., Bruls, Myriam, Connolly, Kristen M., DʼAlessandro, Umberto, Dobaño, Carlota, Gesase, Samwel, Greenwood, Brian, Grimsby, Jonna, Tinto, Halidou, Hamel, Mary J., Hoffman, Irving, Kamthunzi, Portia, Kariuki, Simon, Kremsner, Peter G., Leach, Amanda, Lell, Bertrand, Lennon, Niall J., Lusingu, John, Marsh, Kevin, Martinson, Francis, Molel, Jackson T., Moss, Eli L., Njuguna, Patricia, Ockenhouse, Christian F., Ragama Ogutu, Bernhards, Otieno, Walter, Otieno, Lucas, Otieno, Kephas, Owusu-Agyei, Seth, Park, Daniel J., Pellé, Karell, Robbins, Dana, Russ, Carsten, Ryan, Elizabeth M., Sacarlal, Jahit, Sogoloff, Brian, Sorgho, Hermann, Tanner, Marcel, Theander, Thor, Valea, Innocent, Volkman, Sarah K., Yu, Qing, Lapierre, Didier, Birren, Bruce W., Gilbert, Peter B., and Wirth, Dyann F.

Published
2015
Full Text
View/download PDF

34. Safety and immunogenicity of rVSV[DELTA]G-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

Author

Agnandji, Selidji T., Fernandes, José F., Bache, Emmanuel B., Obiang Mba, Régis M., Brosnahan, Jessica S., Kabwende, Lumeka, Pitzinger, Paul, Staarink, Pieter, Massinga-Loembe, Marguerite, Krähling, Verena, Biedenkopf, Nadine, Fehling, Sarah Katharina, Strecker, Thomas, Clark, David J., Staines, Henry M., Hooper, Jay W., Silvera, Peter, Moorthy, Vasee, Kieny, Marie-Paule, Adegnika, Akim A., Grobusch, Martin P., Becker, Stephan, Ramharter, Michael, Mordmüller, Benjamin, Lell, Bertrand, Krishna, Sanjeev, and Kremsner, Peter G.

Subjects
Vaccines -- Usage -- Safety and security measures, Ebola hemorrhagic fever -- Prevention -- Research, Treatment outcome -- Analysis, Biological sciences
Abstract

Background The rVSV[DELTA]G-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 10.sup.7 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data. Methods and findings A randomised, open-label phase I trial in Lambaréné, Gabon, studied 5 single intramuscular vaccine doses of 3 x 10.sup.3, 3 x 10.sup.4, 3 x 10.sup.5, 3 x 10.sup.6, or 2 x 10.sup.7 PFU in 115 adults and a dose of 2 x 10.sup.7 PFU in 20 adolescents and 20 children. The primary objective was safety and tolerability 28 days post-injection. Immunogenicity, viraemia, and shedding post-vaccination were evaluated as secondary objectives. In adults, mild-to-moderate adverse events were frequent, but there were no serious or severe adverse events related to vaccination. Before vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV antibodies were detected in 11% and 27% of adults, respectively. In adults, 74%-100% of individuals who received a dose 3 x 10.sup.4, 3 x 10.sup.5, 3 x 10.sup.6, or 2 x 10.sup.7 PFU had a [greater than or equal to]4.0-fold increase in geometric mean titres (GMTs) of ZEBOV-GP-specific antibodies at day 28, reaching GMTs of 489 (95% CI: 264-908), 556 (95% CI: 280-1,101), 1,245 (95% CI: 899-1,724), and 1,503 (95% CI: 931-2,426), respectively. Twenty-two percent of adults had a [greater than or equal to]4-fold increase of ZEBOV antibodies, with GMTs at day 28 of 1,015 (647-1,591), 1,887 (1,154-3,085), 1,445 (1,013-2,062), and 3,958 (2,249-6,967) for the same doses, respectively. These antibodies persisted up to day 180 for doses [greater than or equal to]3 x 10.sup.5 PFU. Adults with antibodies before vaccination had higher GMTs throughout. Neutralising antibodies were detected in more than 50% of participants at doses [greater than or equal to]3 x 10.sup.5 PFU. As in adults, no serious or severe adverse events related to vaccine occurred in adolescents or children. At day 2, vaccine RNA titres were higher for adolescents and children than adults. At day 7, 78% of adolescents and 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva. The vaccine induced high GMTs of ZEBOV-GP-specific antibodies at day 28 in adolescents, 1,428 (95% CI: 1,025-1,989), and children, 1,620 (95% CI: 806-3,259), and in both groups antibody titres increased up to day 180. The absence of a control group, lack of stratification for baseline antibody status, and imbalances in male/female ratio are the main limitations of this study. Conclusions Our data confirm the acceptable safety and immunogenicity profile of the 2 x 10.sup.7 PFU dose in adults and support consideration of lower doses for paediatric populations and those who request boosting. Trial registration Pan African Clinical Trials Registry PACTR201411000919191, Author(s): Selidji T. Agnandji 1,2,3, José F. Fernandes 1,2, Emmanuel B. Bache 1, Régis M. Obiang Mba 1, Jessica S. Brosnahan 1,2,3, Lumeka Kabwende 1, Paul Pitzinger 1,2,4, Pieter Staarink [...]

Published
2017
Full Text
View/download PDF

35. Evaluation of intermittent preventive treatment of malaria against group B Streptococcus colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of sulfadoxine/pyrimethamine versus mefloquine

Author

Capan-Melser, Mesküre, Mombo Ngoma, Ghyslain, Akerey-Diop, Daisy, Basra, Arti, Würbel, Heike, Groger, Mirjam, Mackanga, Jean R., Zoleko-Manego, Rella, Schipulle, Ulla, Schwing, Julia, Lötsch, Felix, Rehman, Khalid, Matsiegui, Pierre-Blaise, Agnandji, Selidji T., Adegnika, Ayôla A., Bélard, Sabine, González, Raquel, Kremsner, Peter G., Menendez, Clara, and Ramharter, Michael

Published
2015
Full Text
View/download PDF

38. Birth weight, growth, nutritional status and mortality of infants from Lambaréné and Fougamou in Gabon in their first year of life

Author

Zoleko-Manego, Rella, primary, Mischlinger, Johannes, additional, Dejon-Agobé, Jean Claude, additional, Basra, Arti, additional, Mackanga, J. Rodolphe, additional, Akerey Diop, Daisy, additional, Adegnika, Ayola Akim, additional, Agnandji, Selidji T., additional, Lell, Bertrand, additional, Kremsner, Peter G., additional, Matsiegui, Pierre Blaise, additional, González, Raquel, additional, Menendez, Clara, additional, Ramharter, Michael, additional, and Mombo-Ngoma, Ghyslain, additional

Published
2021
Full Text
View/download PDF

39. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial

Author

Adegnika, Ayola A, primary, de Vries, Sophia G, additional, Zinsou, Frejus J, additional, Honkepehedji, Yabo J, additional, Dejon Agobé, Jean-Claude, additional, Vodonou, Kafui G, additional, Bikangui, Rodrigue, additional, Bouyoukou Hounkpatin, Aurore, additional, Bache, Emmanuel B, additional, Massinga Loembe, Marguerite, additional, van Leeuwen, Remko, additional, Molemans, Marjan, additional, Kremsner, Peter G, additional, Yazdanbakhsh, Maria, additional, Hotez, Peter J, additional, Bottazzi, Maria Elena, additional, Li, Guangzhao, additional, Bethony, Jeffrey M, additional, Diemert, David J, additional, Grobusch, Martin P, additional, Mouwenda, Yoanne D, additional, Betouke Ongwe, Eunice, additional, Nkoma Mouima, Anne-Marie, additional, Nouatin, Odilon P, additional, Edoa, Jean R, additional, Manouana, Prince G, additional, Pinto de Jesus, Susana, additional, Kühne, Vera, additional, Mordmueller, Benjamin, additional, Lell, Bertrand, additional, Agnandji, Selidji T, additional, and Koehler, Carsten, additional

Published
2021
Full Text
View/download PDF

42. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial

Author

Ramharter, Michael, Oyakhirome, Sunny, Klouwenberg, Peter Klein, Adegnika, Ayola A., Agnandji, Selidji T., Missinou, Michel A., Matsiegui, Pierre-Blaise, Mordmuller, Benjamin, Borrmann, Steffen, Kun, Jurgen F., Lell, Bertrand, Krishna, Sanjeev, Graninger, Wolfgang, Issifou, Saadou, and Kremsner, Peter G.

Subjects
Quinine -- Dosage and administration, Malaria -- Drug therapy, Clindamycin -- Dosage and administration, Health, Health care industry
Published
2005

43. Bacterial versus non-bacterial infections: a methodology to support use-case-driven product development of diagnostics

Author

Escadafal, Camille, primary, Geis, Steffen, additional, Siqueira, A M, additional, Agnandji, Selidji T, additional, Shimelis, Techalew, additional, Tadesse, Birkneh Tilahun, additional, Massinga Loembé, Marguerite, additional, Harris, Victoria, additional, Fernandez-Carballo, B Leticia, additional, Macé, Aurélien, additional, Ongarello, Stefano, additional, Rodriguez, William, additional, and Dittrich, Sabine, additional

Published
2020
Full Text
View/download PDF

44. First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa

Author

Abe, Haruka, primary, Ushijima, Yuri, additional, Bikangui, Rodrigue, additional, Ondo, Georgelin N., additional, Zadeh, Vahid R., additional, Pemba, Christelle M., additional, Mpingabo, Patrick I., additional, Igasaki, Yui, additional, Vries, Sophia G., additional, Grobusch, Martin P., additional, Loembe, Marguerite M., additional, Agnandji, Selidji T., additional, Lell, Bertrand, additional, and Yasuda, Jiro, additional

Published
2020
Full Text
View/download PDF

45. Recombinase Polymerase Amplification and Lateral Flow Assay for Ultrasensitive Detection of Low-Density Plasmodium falciparum Infection from Controlled Human Malaria Infection Studies and Naturally Acquired Infections

Author

Lalremruata, Albert, primary, Nguyen, The Trong, additional, McCall, Matthew B. B., additional, Mombo-Ngoma, Ghyslain, additional, Agnandji, Selidji T., additional, Adegnika, Ayôla A., additional, Lell, Bertrand, additional, Ramharter, Michael, additional, Hoffman, Stephen L., additional, Kremsner, Peter G., additional, and Mordmüller, Benjamin, additional

Published
2020
Full Text
View/download PDF

46. Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic

Author

Wang, Jigang, primary, Xu, Chengchao, additional, Wong, Yin Kwan, additional, He, Yingke, additional, Adegnika, Ayôla A, additional, Kremsner, Peter G, additional, Agnandji, Selidji T, additional, Sall, Amadou A, additional, Liang, Zhen, additional, Qiu, Chen, additional, Liao, Fu Long, additional, Jiang, Tingliang, additional, Krishna, Sanjeev, additional, and Tu, Youyou, additional

Published
2020
Full Text
View/download PDF

49. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization

Author

Agnandji, Selidji T., Asante, Kwaku Poku, Lyimo, John, Vekemans, Johan, Soulanoudjingar, Solange S., Owusu, Ruth, Shomari, Mwanajaa, Leach, Amanda, Fernandes, Jose, Dosoo, David, Chikawe, Maria, Issifou, Saadou, Osei-Kwakye, Kingsley, Lievens, Marc, Paricek, Maria, Apanga, Stephen, Mwangoka, Grace, Okissi, Blaise, Kwara, Evans, Minja, Rose, Lange, Jorn, Boahen, Owusu, Kayan, Kingsley, Adjei, George, Chandramohan, Daniel, Jongert, Erik, Demoitie, Marie-Ange, Dubois, Marie-Claude, Carter, Terrel, Vansadia, Preeti, Villafana, Tonya, Sillman, Marla, Savarese, Barbara, Lapierre, Didier, Ballou, William Ripley, Greenwood, Brian, Tanner, Marcel, Cohen, Joe, Kremsner, Peter G., Lell, Bertrand, Owusu-Agyei, Seth, and Abdulla, Salim

Subjects
Immunization -- Usage, Immunization -- Health aspects, Malaria -- Prevention, Malaria vaccine -- Usage, Malaria vaccine -- Health aspects, Malaria vaccine -- Safety and security measures, Health
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results